Rebecca C. Arend

6.5k total citations · 1 hit paper
162 papers, 3.6k citations indexed

About

Rebecca C. Arend is a scholar working on Reproductive Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Rebecca C. Arend has authored 162 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Reproductive Medicine, 61 papers in Oncology and 50 papers in Molecular Biology. Recurrent topics in Rebecca C. Arend's work include Ovarian cancer diagnosis and treatment (64 papers), Endometrial and Cervical Cancer Treatments (32 papers) and PARP inhibition in cancer therapy (22 papers). Rebecca C. Arend is often cited by papers focused on Ovarian cancer diagnosis and treatment (64 papers), Endometrial and Cervical Cancer Treatments (32 papers) and PARP inhibition in cancer therapy (22 papers). Rebecca C. Arend collaborates with scholars based in United States, United Kingdom and Canada. Rebecca C. Arend's co-authors include Donald J. Buchsbaum, J. Michael Straughn, Angelina I. Londoño-Joshi, Rajeev S. Samant, Yonghe Li, Bayley A. Jones, Lyse A. Norian, Pui‐Kai Li, Alba Martínez and Michael J. Roberts and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Rebecca C. Arend

146 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Wnt/β-catenin pathway in ovarian cancer: A review

2013 373 citations Rebecca C. Arend, Angelina I. Londoño-Joshi et al. Gynecologic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rebecca C. Arend United States	35	1.7k	1.1k	668	663	513	162	3.6k
Susana M. Campos United States	28	859 0.5×	1.6k 1.4×	899 1.3×	346 0.5×	330 0.6×	101	3.3k
Hannah Yang United States	30	872 0.5×	1.1k 1.0×	497 0.7×	476 0.7×	512 1.0×	84	2.8k
Jung‐Yun Lee South Korea	32	964 0.6×	1.4k 1.2×	1.5k 2.2×	560 0.8×	1.1k 2.1×	270	4.0k
Beihua Kong China	32	1.2k 0.8×	611 0.5×	1.2k 1.8×	685 1.0×	796 1.6×	121	3.1k
Cláudia Marchetti Italy	33	719 0.4×	968 0.8×	1.5k 2.3×	406 0.6×	885 1.7×	178	3.3k
Nicole Concin Austria	37	1.3k 0.8×	1.4k 1.2×	1.2k 1.8×	777 1.2×	1.0k 2.0×	146	3.9k
Sven Mahner Germany	28	867 0.5×	1.2k 1.1×	650 1.0×	383 0.6×	490 1.0×	140	2.8k
Roshan Agarwal United Kingdom	30	1.7k 1.0×	1.1k 1.0×	667 1.0×	716 1.1×	130 0.3×	61	3.8k
Michalis Liontos Greece	26	1.5k 0.9×	889 0.8×	196 0.3×	469 0.7×	140 0.3×	125	2.7k
Stephen A. Cannistra United States	30	2.0k 1.2×	1.9k 1.6×	2.0k 3.0×	756 1.1×	475 0.9×	46	5.1k

Countries citing papers authored by Rebecca C. Arend

Since Specialization

Citations

This map shows the geographic impact of Rebecca C. Arend's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rebecca C. Arend with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rebecca C. Arend more than expected).

Fields of papers citing papers by Rebecca C. Arend

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rebecca C. Arend. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rebecca C. Arend. The network helps show where Rebecca C. Arend may publish in the future.

Co-authorship network of co-authors of Rebecca C. Arend

This figure shows the co-authorship network connecting the top 25 collaborators of Rebecca C. Arend. A scholar is included among the top collaborators of Rebecca C. Arend based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rebecca C. Arend. Rebecca C. Arend is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Clarke, Megan A., Jared A. Fisher, Nicolas Wentzensen, et al.. (2025). State-Specific Incidence of Endometrial Cancer in the United States by Histologic Subtype Corrected for Hysterectomy Prevalence from 2010 to 2019. Cancer Epidemiology Biomarkers & Prevention. 34(8). 1269–1276.

Valentine, Mark C., Mary M. Mullen, Matthew A. Powell, et al.. (2025). Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response. Cancer Research. 85(18). 3558–3570. 1 indexed citations

Arend, Rebecca C., et al.. (2025). The Association Between Medroxyprogesterone Acetate Exposure and Cerebral Meningioma Among a Medicaid Population. Epidemiologia. 6(4). 58–58. 1 indexed citations

Vogel, Rachel I., Patricia Jewett, Helen M. Parsons, et al.. (2025). Time Burden in Patients With Metastatic Breast and Ovarian Cancer from Clinic and Home Demands. JAMA Network Open. 8(12). e2549957–e2549957.

O’Brien, Emily C., Christopher Mayer, & Rebecca C. Arend. (2025). Exploring T-cell bispecific antibodies in gynecologic malignancy. Gynecologic Oncology Reports. 59. 101772–101772. 2 indexed citations

Liu, Joyce F., Stéphanie Gaillard, Andrea E. Wahner Hendrickson, et al.. (2024). Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial. JCO Precision Oncology. 8(8). e2300693–e2300693. 6 indexed citations

Bouberhan, Sara, Konstantinos Papadimitriou, Rebecca C. Arend, et al.. (2024). A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5632–TPS5632. 7 indexed citations

Cheng, Michelle Y., Rebecca C. Arend, Kimberly Levinson, et al.. (2024). Improved efficacy of therapeutic HPV DNA vaccine using intramuscular injection with electroporation compared to conventional needle and needle-free jet injector methods. Cell & Bioscience. 14(1). 154–154.

Meza‐Perez, Selene, Aarón Silva-Sánchez, Casey D. Morrow, et al.. (2024). Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine. Cell Host & Microbe. 32(7). 1177–1191.e7. 17 indexed citations

10.

Shiels, Meredith S., et al.. (2024). Five-Year Relative Survival Rates of Women Diagnosed with Uterine Cancer by County-Level Socioeconomic Status Overall and across Histology and Race/Ethnicity. Cancers. 16(15). 2747–2747. 2 indexed citations

11.

Richardson, Debra J., Jill Tseng, Theresa L. Werner, et al.. (2022). 33 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer. Gynecologic Oncology Reports. 44. S16–S17. 2 indexed citations

12.

Ethier, Josée-Lyne, Katherine C. Fuh, Rebecca C. Arend, et al.. (2022). State of the Biomarker Science in Ovarian Cancer: A National Cancer Institute Clinical Trials Planning Meeting Report. JCO Precision Oncology. 6(6). e2200355–e2200355. 4 indexed citations

13.

Evans, Elizabeth, Jim Abraham, Jian Zhang, et al.. (2022). Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171). Gynecologic Oncology. 166. S100–S100. 4 indexed citations

14.

Scalise, Carly Bess, Ashwini A. Katre, Selene Meza‐Perez, et al.. (2021). Sequential modulation of the Wnt/β-catenin signaling pathway enhances tumor-intrinsic MHC I expression and tumor clearance. Gynecologic Oncology. 164(1). 170–180. 16 indexed citations

15.

Meza‐Perez, Selene, Ashwini A. Katre, Troy D. Randall, et al.. (2020). Neutralization of TGFβ Improves Tumor Immunity and Reduces Tumor Progression in Ovarian Carcinoma. Molecular Cancer Therapeutics. 20(3). 602–611. 7 indexed citations

16.

Arend, Rebecca C., Anne Van Arsdale, David W. Doo, et al.. (2019). Neutrophilia and mortality in women with uterine carcinosarcoma. International Journal of Gynecological Cancer. 29(8). 1258–1263. 3 indexed citations

17.

Arend, Rebecca C., Angelina I. Londoño, Haller J. Smith, et al.. (2018). Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research. 16(5). 813–824. 47 indexed citations

18.

Arend, Rebecca C., et al.. (2018). Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm. The Oncologist. 23(12). 1533–1545. 19 indexed citations

19.

Arend, Rebecca C., Britt Erickson, Yanhua Wang, et al.. (2018). Insulin‐like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Medicine. 7(3). 616–625. 4 indexed citations

20.

Londoño-Joshi, Angelina I., Rebecca C. Arend, Wenyan Lü, et al.. (2014). Effect of Niclosamide on Basal-like Breast Cancers. Molecular Cancer Therapeutics. 13(4). 800–811. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact